|
Oxycyte is an experimental third-generation perfluorocarbon (PFC) therapeutic oxygen carrier invented by Leland Clark and developed by Oxygen Biotherapeutics, Inc. (OBI; formerly Synthetic Blood International). It is designed to enhance oxygen delivery to damaged tissues. ==Product== When used as an intravenous emulsion, Oxycyte can carry as much as five times more oxygen than hemoglobin, making it an effective means of transporting oxygen to tissues and carrying carbon dioxide to the lungs for disposal.〔(Oxygen Biotherapeutics, Inc. ) Corporate website.〕 Like all PFC-based products, Oxycyte is not a complete blood substitute. Because Oxycyte is a PFC, and not based on hemoglobin, it does not have the safety issues associated with hemoglobin-based products; there have been no adverse events in company clinical trials that were related to Oxycyte. OBI believes that Oxycyte has a very favorable risk-benefit profile for its potential indications. OBI has received approval from Swissmedic and the Israeli Ministry of Health to conduct a Phase II, dose escalation, clinical trial in Switzerland and Israel using Oxycyte as an emergency treatment in traumatic brain injury. The company promotes Oxycyte as having potential for use in multiple indications, including traumatic brain injury, sickle cell crisis, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetic wounds and ulcers and cosmetic applications. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Oxycyte」の詳細全文を読む スポンサード リンク
|